Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Vandana Singh

REVEALED: Cidara therapeutics analyst says lead influenza candidate is strategically attractive | Vintage Vibes

Vaccine

JP Morgan initiated coverage of Cidara Therapeutics Inc. (NASDAQ:CDTX) on Friday, citing its lead asset, CD388, for influenza, underscoring the game-changing potential of the product and multi-billion dollar potential in the U.S. alone.

Analyst Anupam Rama says across doses, prevention efficacy was ahead of known vaccine benchmarks across various populations, with the highest dose (450mg) showing a prevention efficacy of around 76% with no major safety concerns.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.